Novozymes A/S (OTCMKTS:NVZMY) Short Interest Up 1,727.7% in August

Novozymes A/S (OTCMKTS:NVZMY) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 34,196 shares, a growth of 1,727.7% from the August 15th total of 1,871 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 46,883 shares, the short-interest ratio is currently 0.7 days.

Novozymes A/S Stock Down 2.2%

Shares of NVZMY stock traded down $1.46 on Thursday, hitting $65.89. 18,855 shares of the stock were exchanged, compared to its average volume of 66,569. The company has a current ratio of 1.67, a quick ratio of 1.03 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $27.31 billion, a P/E ratio of 41.70, a price-to-earnings-growth ratio of 2.98 and a beta of 0.93. The business has a 50-day moving average of $66.29 and a 200 day moving average of $61.45. Novozymes A/S has a fifty-two week low of $49.90 and a fifty-two week high of $75.27.

Novozymes A/S (OTCMKTS:NVZMY) last posted its quarterly earnings data on Thursday, August 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.16). Novozymes A/S had a return on equity of 6.60% and a net margin of 14.70%.The firm had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.27 billion. Equities analysts anticipate that Novozymes A/S will post 2.47 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Zacks Research upgraded shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a report on Monday, June 8th. Kepler Capital Markets upgraded shares of Novozymes A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy”.

Hedge Funds Weigh In On Novozymes A/S

An institutional investor recently raised its position in Novozymes A/S stock. Elefante Mark B grew its holdings in Novozymes A/S (OTCMKTS:NVZMY) by 73.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,900 shares of the biotechnology company’s stock after purchasing an additional 2,500 shares during the period. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent quarter. Institutional investors own 0.03% of the company’s stock.

Novozymes A/S Company Profile

Novozymes A/S was a Danish biotechnology company that developed and commercialized enzymes, microorganisms and other biological solutions for industrial and consumer applications. Its technologies were designed to help customers improve production efficiency, reduce resource use and develop more sustainable products and processes.

The company supplied biological products and related solutions to a range of industries, including food and beverages, household care, agriculture, animal health, bioenergy and industrial manufacturing.